Close Menu

New synthetic biology tools may enable genetic engineers to play with metabolic pathways and the genetic code, according to the Economist.

For instance, it reports that Antheia, a firm founded by Christina Smolke, is working on designing new metabolic pathways to cheaply produce opiates for pain relief and to devise ones that are less addictive.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.

Canadian regulators are beginning to share information from new drug studies, Undark reports.

In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.

Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.